Compare Stocks: PACB, BRKR, and QTRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRKR Bruker	$63.96 +5.4%	$58.09	$30.09 ▼ $65.30	$9.71B	1.26	2.36 million shs	881,253 shs
PACB Pacific Biosciences of California	$1.42 +5.6%	$1.35	$1.07 ▼ $2.73	$439.82M	2.31	6.56 million shs	3.33 million shs
QTRX Quanterix	$3.07 +5.5%	$3.19	$2.15 ▼ $8.77	$144.94M	1.04	923,656 shs	358,524 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRKR Bruker	+8.83%	+11.46%	+5.20%	+6.01%	+82.41%
PACB Pacific Biosciences of California	0.00%	+3.88%	+10.74%	-4.29%	+8.94%
QTRX Quanterix	+6.99%	+9.81%	-0.34%	-14.16%	-44.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRKR Bruker	$63.96 +5.4%	$58.09	$30.09 ▼ $65.30	$9.71B	1.26	2.36 million shs	881,253 shs
PACB Pacific Biosciences of California	$1.42 +5.6%	$1.35	$1.07 ▼ $2.73	$439.82M	2.31	6.56 million shs	3.33 million shs
QTRX Quanterix	$3.07 +5.5%	$3.19	$2.15 ▼ $8.77	$144.94M	1.04	923,656 shs	358,524 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRKR Bruker	+8.83%	+11.46%	+5.20%	+6.01%	+82.41%
PACB Pacific Biosciences of California	0.00%	+3.88%	+10.74%	-4.29%	+8.94%
QTRX Quanterix	+6.99%	+9.81%	-0.34%	-14.16%	-44.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRKR Bruker	2.43	Hold	$57.00	-10.87% Downside
PACB Pacific Biosciences of California	1.83	Reduce	$1.71	21.02% Upside
QTRX Quanterix	1.67	Reduce	$3.00	-2.28% Downside

Current Analyst Ratings Breakdown

Latest PACB, BRKR, and QTRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	BRKR Bruker	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$45.00 ➝ $65.00
9/9/2026	PACB Pacific Biosciences of California	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$1.50 ➝ $1.35
9/2/2026	BRKR Bruker	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/31/2026	BRKR Bruker	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/25/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/17/2026	QTRX Quanterix	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$4.00 ➝ $3.00
8/11/2026	PACB Pacific Biosciences of California	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	QTRX Quanterix	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$4.00 ➝ $3.00
8/7/2026	QTRX Quanterix	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/5/2026	BRKR Bruker	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$50.00

(Data available from 9/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRKR Bruker	$3.44B	2.84	$3.87 per share	16.51	$16.28 per share	3.93
PACB Pacific Biosciences of California	$160.01M	2.75	$0.83 per share	1.70	$0.02 per share	70.75
QTRX Quanterix	$138.90M	1.05	N/A	N/A	$6.33 per share	0.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRKR Bruker	-$8.60M	-$0.70	N/A	26.32	1.71	-2.35%	12.47%	4.91%	11/2/2026 (Estimated)
PACB Pacific Biosciences of California	-$546.38M	-$0.43	N/A	N/A	N/A	-82.49%	-5,752.12%	-19.52%	11/3/2026 (Estimated)
QTRX Quanterix	-$107.15M	-$2.63	N/A	N/A	N/A	-80.25%	-26.09%	-19.03%	11/9/2026 (Estimated)

Latest PACB, BRKR, and QTRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	QTRX Quanterix	-$0.4103	-$1.04	-$0.6297	-$1.04	$37.48 million	$32.91 million
8/4/2026	Q2 2026	BRKR Bruker	$0.3849	$0.49	+$0.1051	-$0.41	$853.57 million	$838.50 million
8/3/2026	Q2 2026	PACB Pacific Biosciences of California	-$0.1280	-$0.14	-$0.0120	-$0.14	$42.90 million	$39.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRKR Bruker	$0.20	0.33%	+4.56%	N/A	N/A
PACB Pacific Biosciences of California	N/A	N/A	N/A	N/A	N/A
QTRX Quanterix	N/A	N/A	N/A	N/A	N/A

Latest PACB, BRKR, and QTRX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/14/2026	BRKR Bruker	quarterly	$0.05	0.35%	9/21/2026	9/21/2026	10/7/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRKR Bruker	0.76	1.85	0.92
PACB Pacific Biosciences of California	N/A	4.92	4.03
QTRX Quanterix	N/A	3.40	2.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRKR Bruker	79.52%
PACB Pacific Biosciences of California	N/A
QTRX Quanterix	86.48%

Insider Ownership

Company	Insider Ownership
BRKR Bruker	27.20%
PACB Pacific Biosciences of California	3.70%
QTRX Quanterix	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRKR Bruker	11,085	152.36 million	110.92 million	Optionable
PACB Pacific Biosciences of California	485	310.83 million	299.33 million	Optionable
QTRX Quanterix	450	47.29 million	46.58 million	Optionable

PACB, BRKR, and QTRX Headlines

Recent News About These Companies

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 16, 2026

September 17 at 7:06 AM | biospace.comB

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 16 at 9:00 PM | businesswire.com

Quanterix average analyst price target decreased by 18.18% to $3.06

September 15 at 8:23 AM | msn.com

Quanterix Names Yuri Fesko Chief Medical Officer

September 14 at 2:25 PM | rttnews.com

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

September 14 at 9:23 AM | finance.yahoo.com

Quanterix Names Dr. Yuri Fesko Chief Medical Officer

September 14 at 8:00 AM | businesswire.com

3,635,411 Shares in Quanterix Corporation $QTRX Bought by BlackRock Inc.

September 4, 2026 | marketbeat.com

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

August 17, 2026 | finance.yahoo.com

Quanterix Corporation

August 16, 2026 | edition.cnn.com

Quanterix Corp (QTRX) (Q2 2026) Earnings Call Highlights: Revenue Miss and Guidance Cut Amid ...

August 10, 2026 | finance.yahoo.com

Quanterix Names Jim Gute Chief Commercial Officer

August 10, 2026 | businesswire.com

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12

August 6, 2026 | aol.comA

Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026

August 4, 2026 | lasvegassun.comL

Quanterix: Trading Below 1x Sales Despite A Changing Story

July 20, 2026 | seekingalpha.com

Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 16, 2026 | businesswire.com

Quanterix rises on coverage win for Alzheimer’s test

July 15, 2026 | seekingalpha.com

Anthem Blue Cross and Blue Shield Establishes Commercial Coverage for LucentAD® Complete; Quanterix to Present New Data Highlighting Multi-Analyte Advantages

July 14, 2026 | businesswire.com

Quanterix (QTRX) Stock Fair Value Falls After Analysts Cut Price Targets

July 9, 2026 | finance.yahoo.com

Quanterix stock is popping in pre-market: Here's why

June 24, 2026 | msn.com

Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 16, 2026 | businesswire.com

Quanterix Shareholders Reject Equity Plan at 2026 Meeting

June 10, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB, BRKR, and QTRX Company Descriptions

Bruker NASDAQ:BRKR

$63.96 +3.29 (+5.41%)

As of 12:10 PM Eastern

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

Pacific Biosciences of California NASDAQ:PACB

$1.42 +0.08 (+5.60%)

As of 12:10 PM Eastern

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Quanterix NASDAQ:QTRX

$3.07 +0.16 (+5.50%)

As of 12:10 PM Eastern

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PACB, BRKR, and QTRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PACB, BRKR, and QTRX Earnings

Compare Dividends

Latest PACB, BRKR, and QTRX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PACB, BRKR, and QTRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB, BRKR, and QTRX Company Descriptions

Bruker NASDAQ:BRKR

Pacific Biosciences of California NASDAQ:PACB

Quanterix NASDAQ:QTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PACB, BRKR, and QTRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PACB, BRKR, and QTRX Earnings

Compare Dividends

Latest PACB, BRKR, and QTRX Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PACB, BRKR, and QTRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB, BRKR, and QTRX Company Descriptions

Bruker NASDAQ:BRKR

Pacific Biosciences of California NASDAQ:PACB

Quanterix NASDAQ:QTRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools